

## Targeted Lung Denervation Bibliography

- Slebos, D.J., Shah, P. L., Herth, F. J., (...) Valipour, A. on behalf of the AIRFLOW-2 Study Group (2019) **Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe COPD (AIRFLOW): A Multicenter Randomized Controlled Trial.** *Am J Respir Crit Care Med.* doi: 10.1164/rccm.201903-0624OC (epub)
- Valipour, A., Shah, P. L., Pison, C., (...) Slebos, D.J. on behalf of the AIRFLOW-1 Study Group (2019) **Safety and Dose Study of Targeted Lung Denervation in Moderate/Severe COPD Patients.** *Respiration* 2019. doi: 10.1159/000500463 (epub)
- Hummel, J. P., Mayse, M. L., Dimmer, S., & Johnson, P. J. (2019) **Physiologic and histopathologic effects of targeted lung denervation in an animal model.** *J Appl Physiol* (1985), 126(1), 67-76. doi: 10.1152/jappphysiol.00565.2018
- Valipour, A., Asadi, S., Pison, C., Jondot, M., Kessler, R., Bennedif, K., (. . .) Mayse, M. (2018). **Long-term safety of bilateral targeted lung denervation in patients with COPD.** *Int J Chron Obstruct Pulmon Dis*, 13, 2163-2172. doi: 10.2147/COPD.S158748
- Koegelenberg, C. F., Theron, J., Slebos, D. J., Klooster, K., Mayse, M., & Gosens, R. (2016). **Antimuscarinic Bronchodilator Response Retained after Bronchoscopic Vagal Denervation in Chronic Obstructive Pulmonary Disease Patients.** *Respiration*, 92(1), 58-60. doi: 10.1159/000447641
- Kistemaker, L. E., Slebos, D. J., Meurs, H., Kerstjens, H. A., & Gosens, R. (2015). **Anti-inflammatory effects of targeted lung denervation in patients with COPD.** *Eur Respir J*, 46(5), 1489-1492. doi: 10.1183/13993003.00413-2015
- Slebos, D. J., Klooster, K., Koegelenberg, C. F., Theron, J., Styen, D., Valipour, A., (. . .) Bolliger, C. T. (2015). **Targeted lung denervation for moderate to severe COPD: a pilot study.** *Thorax*, 70(5), 411-419. doi: 10.1136/thoraxjnl-2014-206146